(PubMed) Perrig WJ, Perrig P, Stahelin HB
What is happening now is that we are treating many patients who would benefit most from metabolic surgery with OMM, while still failing to treat the vast majority of people living with obesity who would benefit from any evidence-based treatment
Neuropharmacology (2018) 136(Pt B):2806
The benefits of metabolic surgery appear to be sustained for many years
The FDA has approved three medications specifically for weight loss as of my preparation of this content: liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound) (National Institute of Diabetes and Digestive and Kidney Diseases, 2026b)
Its unique action targets key metabolic pathways to foster effective, long-term results